Pharmakokinetik am vorderen Augenabschnitt

[1]  G. Schwartz,et al.  Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial , 2013, British Journal of Ophthalmology.

[2]  H. Sasaki,et al.  Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations , 2013, Clinical ophthalmology.

[3]  E. Stefánsson,et al.  Dexamethasone eye drops containing γ-cyclodextrin-based nanogels. , 2013, International journal of pharmaceutics.

[4]  T. Oshika,et al.  Time course of changes in ocular wavefront aberration after administration of eye ointment , 2012, Eye.

[5]  M. Shimizu,et al.  Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. , 2012, The Journal of toxicological sciences.

[6]  N. Schrage,et al.  The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite®-preserved versus unpreserved eye drops , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  Eugenio A. Maul,et al.  Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial , 2011, British Journal of Ophthalmology.

[8]  Ashim K. Mitra,et al.  Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.

[9]  Yoshihisa Shirasaki.  Molecular design for enhancement of ocular penetration. , 2008, Journal of pharmaceutical sciences.

[10]  S. Krishnakumar,et al.  Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.

[11]  A. Mundada,et al.  Formulation and Evaluation of Ciprofloxacin Hydrochloride Soluble Ocular Drug Insert , 2008, Current eye research.

[12]  A. Ludwig,et al.  The use of mucoadhesive polymers in ocular drug delivery. , 2005, Advanced drug delivery reviews.

[13]  C. Baudouin.  Allergic reaction to topical eyedrops , 2005 .

[14]  S. Majumdar,et al.  Role of metabolism in ocular drug delivery. , 2004, Current drug metabolism.

[15]  Rubiana M Mainardes,et al.  Drug delivery systems: past, present, and future. , 2004, Current drug targets.

[16]  Anuj Chauhan,et al.  Ophthalmic drug delivery through contact lenses. , 2004, Investigative ophthalmology & visual science.

[17]  V. Ganapathy,et al.  Transport of Amino Acid-Based Prodrugs by the Na+- and Cl--Coupled Amino Acid Transporter ATB0,+ and Expression of the Transporter in Tissues Amenable for Drug Delivery , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  L. Balant,et al.  Ocular Availability of Gentamicin in Small Animals After Topical Administration of a Conventional Eye Drop Solution and a Novel Long Acting Bioadhesive Ophthalmic Drug Insert , 1995, Pharmaceutical Research.

[19]  J. Hadgraft,et al.  Evaluation of Mucoadhesive Polymers in Ocular Drug Delivery. I. Viscous Solutions , 1991, Pharmaceutical Research.

[20]  G. Ousler,et al.  Evaluation of the comfort of Alphagan® P compared with Alphagan® in irritated eyes , 2003, Advances in therapy.

[21]  S. Gupta,et al.  Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. , 2003, Investigative ophthalmology & visual science.

[22]  R. Noecker,et al.  Effects of common ophthalmic preservatives on ocular health , 2001, Advances in therapy.

[23]  Y. Sawada,et al.  Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[24]  A Shedden,et al.  Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. , 2001, Clinical therapeutics.

[25]  Hong-Ru Lin,et al.  Carbopol/pluronic phase change solutions for ophthalmic drug delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[26]  J. Streilein,et al.  Effects of experimental ocular inflammation on ocular immune privilege. , 1999, Investigative ophthalmology & visual science.

[27]  Huff Jw,et al.  Cytotoxicity evaluation of multipurpose contact lens solutions using an in vitro test battery , 1999 .

[28]  L. Balant,et al.  Optimized release of dexamethasone and gentamicin from a soluble ocular insert for the treatment of external ophthalmic infections. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[29]  K. Kontturi,et al.  Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. , 1997, Investigative ophthalmology & visual science.

[30]  R. Gurny,et al.  Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[31]  B. Gebhardt,et al.  Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. , 1995, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[32]  T. Zimmerman,et al.  Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion. , 1992, American journal of ophthalmology.

[33]  R. Brubaker,et al.  Flow of aqueous humor in humans [The Friedenwald Lecture]. , 1991, Investigative ophthalmology & visual science.

[34]  A. Urtti,et al.  Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits , 1990 .

[35]  R. Schoenwald.  Ocular drug delivery. Pharmacokinetic considerations. , 1990, Clinical pharmacokinetics.

[36]  C. Chiang,et al.  Corneal and scleral penetration studies of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor. , 1990, Journal of ocular pharmacology.

[37]  S. Tseng,et al.  Paracellular permeability of corneal and conjunctival epithelia. , 1989, Investigative ophthalmology & visual science.

[38]  G. Grass,et al.  Mechanisms of corneal drug penetration. II: Ultrastructural analysis of potential pathways for drug movement. , 1988, Journal of pharmaceutical sciences.

[39]  T. F. Patton,et al.  Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption , 1987 .

[40]  M. F. Saettone,et al.  Vehicle effects on ophthalmic bioavailability: the influence of different polymers on the activity of pilocarpine in rabbit and man , 1982, The Journal of pharmacy and pharmacology.

[41]  G. Raviola.  The structural basis of the blood-ocular barriers. , 1977, Experimental eye research.

[42]  A. Tønjum.  Permeability of horseradish peroxidase in the rabbit corneal epithelium. , 2009, Acta ophthalmologica.

[43]  F. B. Hoefle,et al.  Recent studies on the nature and function of the corneal endothelial barrier. , 1973, Experimental eye research.